Abeona Therapeutics Inc. (0H7R.L)
USD 6.78
(-3.28%)
USD 6.78
(-3.28%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 302 Thousand USD | -823.05% |
| 2022 | -3.16 Million USD | -116.05% |
| 2021 | -1.46 Million USD | 92.73% |
| 2020 | -20.13 Million USD | -132.1% |
| 2019 | -8.67 Million USD | 75.69% |
| 2018 | -35.7 Million USD | -121.03% |
| 2017 | -16.15 Million USD | -65.39% |
| 2016 | -9.76 Million USD | -1039.04% |
| 2015 | 1.04 Million USD | 12.43% |
| 2014 | 925 Thousand USD | -51.75% |
| 2013 | 1.91 Million USD | -53.66% |
| 2012 | 4.13 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -1.66 Million USD | -130.25% |
| 2024 Q1 | -724 Thousand USD | -0.42% |
| 2023 Q3 | -751 Thousand USD | -128.21% |
| 2023 FY | 302 Thousand USD | 109.55% |
| 2023 Q2 | 2.66 Million USD | 399.77% |
| 2023 Q4 | -721 Thousand USD | 3.99% |
| 2023 Q1 | -888 Thousand USD | 5.63% |
| 2022 FY | -3.16 Million USD | -116.05% |
| 2022 Q3 | -1.08 Million USD | 81.94% |
| 2022 Q2 | -6 Million USD | -683.31% |
| 2022 Q1 | -767 Thousand USD | -142.52% |
| 2022 Q4 | -940.99 Thousand USD | 13.27% |
| 2021 Q2 | -1.09 Million USD | -1.29% |
| 2021 Q4 | 1.8 Million USD | 266.42% |
| 2021 Q3 | -1.08 Million USD | 1.36% |
| 2021 Q1 | -1.08 Million USD | 82.62% |
| 2021 FY | -1.46 Million USD | 92.73% |
| 2020 Q3 | -969 Thousand USD | 84.14% |
| 2020 Q2 | -6.1 Million USD | 10.4% |
| 2020 FY | -20.13 Million USD | -132.1% |
| 2020 Q1 | -6.81 Million USD | 29.02% |
| 2020 Q4 | -6.24 Million USD | -544.27% |
| 2019 Q2 | -16.3 Million USD | -38.94% |
| 2019 Q4 | -9.6 Million USD | 12.02% |
| 2019 Q3 | -10.91 Million USD | 33.05% |
| 2019 FY | -8.67 Million USD | 75.69% |
| 2019 Q1 | -11.73 Million USD | -30.59% |
| 2018 Q1 | -7.63 Million USD | -38.97% |
| 2018 Q3 | -11.44 Million USD | -49.75% |
| 2018 Q4 | -8.98 Million USD | 21.44% |
| 2018 FY | -35.7 Million USD | -121.03% |
| 2018 Q2 | -7.64 Million USD | -0.12% |
| 2017 Q3 | -3.05 Million USD | 45.3% |
| 2017 Q2 | -5.59 Million USD | -177.88% |
| 2017 Q1 | -2.01 Million USD | -885.94% |
| 2017 FY | -16.15 Million USD | -65.39% |
| 2017 Q4 | -5.49 Million USD | -79.56% |
| 2016 Q3 | 184 Thousand USD | -14.02% |
| 2016 FY | -9.76 Million USD | -1039.04% |
| 2016 Q4 | 256 Thousand USD | 39.13% |
| 2016 Q2 | 214 Thousand USD | -8.94% |
| 2016 Q1 | 235 Thousand USD | 9.3% |
| 2015 Q4 | 215 Thousand USD | -24.56% |
| 2015 Q2 | 282 Thousand USD | 9.3% |
| 2015 Q1 | 258 Thousand USD | 10.26% |
| 2015 FY | 1.04 Million USD | 12.43% |
| 2015 Q3 | 285 Thousand USD | 1.06% |
| 2014 FY | 925 Thousand USD | -51.75% |
| 2014 Q4 | 234 Thousand USD | -0.85% |
| 2014 Q2 | 247 Thousand USD | 18.75% |
| 2014 Q3 | 236 Thousand USD | -4.45% |
| 2014 Q1 | 208 Thousand USD | 28.4% |
| 2013 FY | 1.91 Million USD | -53.66% |
| 2013 Q1 | 1.15 Million USD | 23.3% |
| 2013 Q2 | 414 Thousand USD | -64.28% |
| 2013 Q3 | 182 Thousand USD | -56.04% |
| 2013 Q4 | 162 Thousand USD | -10.99% |
| 2012 FY | 4.13 Million USD | 0.0% |
| 2012 Q4 | 940 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| uniQure N.V. | 2.21 Million USD | 86.366% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 100.354% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 98.256% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 196.486% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 97.959% |
| Imunon, Inc. | -720 Thousand USD | 141.944% |
| Dynavax Technologies Corporation | 182.11 Million USD | 99.834% |
| Editas Medicine, Inc. | -99.52 Million USD | 100.303% |
| FibroGen, Inc. | 128.9 Million USD | 99.766% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 103.157% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 199.67% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 99.984% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 99.972% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 99.942% |
| Verastem, Inc. | -62 Thousand USD | 587.097% |
| Zoetis Inc. | 5.83 Billion USD | 99.995% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 99.996% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 100.666% |
| Homology Medicines, Inc. | -7.22 Million USD | 104.178% |
| Nektar Therapeutics | 53.47 Million USD | 99.435% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 203.425% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 101.533% |
| Perrigo Company plc | 1.68 Billion USD | 99.982% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | 99.587% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 99.999% |
| Illumina, Inc. | 2.74 Billion USD | 99.989% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 99.998% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 99.994% |
| Heron Therapeutics, Inc. | 10.04 Million USD | 96.993% |
| Waters Corporation | 1.76 Billion USD | 99.983% |
| Biogen Inc. | 7.3 Billion USD | 99.996% |
| Evolus, Inc. | 140.52 Million USD | 99.785% |
| Adicet Bio, Inc. | -6.09 Million USD | 104.952% |
| bluebird bio, Inc. | -4.03 Million USD | 107.494% |
| Geron Corporation | -123.5 Million USD | 100.245% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 99.98% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 99.917% |
| Myriad Genetics, Inc. | 476.4 Million USD | 99.937% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 100.076% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 99.986% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 100.969% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 99.984% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 99.997% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 99.991% |
| OPKO Health, Inc. | 318.12 Million USD | 99.905% |
| Exelixis, Inc. | 1.75 Billion USD | 99.983% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 99.937% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 99.877% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 99.961% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 99.953% |
| Blueprint Medicines Corporation | 236.58 Million USD | 99.872% |
| Insmed Incorporated | 239.63 Million USD | 99.874% |
| TG Therapeutics, Inc. | 219.1 Million USD | 99.862% |
| Incyte Corporation | 3.44 Billion USD | 99.991% |
| Emergent BioSolutions Inc. | 343.9 Million USD | 99.912% |